

Update Information

February 2009

DDIS

Division of
Drug Information Service

Subscriber Information

2009 CD-ROM (1997-current) disc return procedures: It is not necessary to return your monthly outdated (1997-previous month) Index Record disc to *IDIS*. After you have checked your new monthly Index Record disc, please destroy the previous month's disc. The Article disc is a permanent file, NEVER DISCARD! Place the disc at the front of your current article disc file in chronological order for easy access.

IDIS Web site: Iowa Drug Information Service has a Web site with a link to The University of Iowa. Copies of the *World of Drug Information* newsletter, FDA Approval Packages and a form to request a CD-ROM or Web trial can be found here. You can also send us an e-mail message directly from our Web site. The address is:
<http://www.uiowa.edu/~idis/>.

IDIS toll-free number: A toll-free number is available to our U.S. subscribers for questions, comments or inquiries. The number is 1-800-525-4347 (1-800-525-*IDIS*). We encourage you to make use of this number.

Retrieval Software Sublicense Agreement (RSSA): It is not necessary for CD-ROM subscribers to sign an RSSA agreement for their 2009 *IDIS* subscription. A copy of the RSSA will be enclosed with each monthly update shipment.

CD-ROM Retrospective Articles: The 1997 - 2008 CD-ROM articles are available for purchase. Please check your 2009 Price Sheet for cost information.

NEW DRUG TERMS

	<u>NUMBER</u>
CLARA CELL 10.....	92000316
FMFES, 4-.....	78040198
HLA-DR-2.....	14000063
ISOLEUCYL-PROLYL-PROLINE.....	95000327
LC-150444.....	68200434
LY-2112688.....	92000315
PD-0332991.....	10120905
PLERIXAFOR.....	14000064
SILODOSIN.....	12160425
TRU-015.....	14000062
VALYL-PROLYL-PROLINE.....	95000331
ZATARIA MULTIFLORA.....	92510252

NEW DISEASE TERMS

	<u>NUMBER</u>
CARDIOMYOPATHY, TAKOTSUBO.....	429.83
TUMOR, NEUROENDOCRINE.....	209.

DRUG NAME/NUMBER CHANGES

<u>OLD TERM</u>	<u>NUMBER</u>	<u>NEW TERM</u>	<u>NUMBER</u>
VEGF-TRAP	14000511	AFLIBERCEPT	14000511

CONTINUING EDUCATION ARTICLES

Article Number 610481: Anonymous. Silodosin (Rapaflo) for Benign Prostatic Hyperplasia. *Med Lett Drugs Ther* 2009, 51:3-4. (0.1 CEU)

Article Number 610480: Anonymous. PPI Interactions with Clopidogrel. *Med Lett Drugs Ther* 2009, 51:2-3. (*IDIS* Note: The 1.0 Hour of CE Credit is for All Articles in the Issue, Article Numbers 610479-610481). (0.1 CEU)

Article Number 610478: Anonymous. A Granisetron Patch (Sancuso). (*IDIS* Note: The 1.0 Hour of CE Credit is for All Articles in the Issue, Article Numbers 610475-610478). *Med Lett Drugs Ther* 2008, 50:103-104. (0.1 CEU)

Article Number 610477: Anonymous. Drugs that May Cause Psychiatric Symptoms. (*IDIS* Note: The 1.0 Hour of CE Credit is for All Articles in the Issue, Article Numbers 610475-610478) *Med Lett Drugs Ther* 2008, 50:100-103. (0.1 CEU)

Article Number 610476: Anonymous. Antiviral Drugs for Influenza. *Med Lett Drugs Ther* 2008, 50:98-104. (*IDIS* Note: The 1.0 Hour of CE Credit is for All Articles in the Issue, Article Numbers 610475-610478) (0.1 CEU)

Article Number 610475: Anonymous. CRP and Statins for Primary Prevention of Coronary Artery Disease. (*IDIS* Note: The 1.0 Hour of CE Credit is for All Articles in the Issue, Article Numbers 610475-610478). *Med Lett Drugs Ther* 2008, 50:97-98. (0.1 CEU)

Article Number 610457: Poust J. Targeting Metastatic Melanoma. (*IDIS* Note: The 1.5 Hours of CE Credit is for All Articles in the Issue, Article Numbers 610455-610457). *Am J Health-Syst Pharm* 2008, 65:S9-S15. (0.15 CEU)

Article Number 610456: Trinh VA. Current Management of Metastatic Melanoma. (*IDIS* Note: The 1.5 Hours of CE Credit is for All Articles in the Issue, Article Numbers 610455-610457) *Am J Health-Syst Pharm* 2008, 65:S3-S9. (0.15 CEU)

(over)

CONTINUING EDUCATION ARTICLES-CONTINUED

Article Number 610455: Trinh VA, Poust J. Emerging Strategies for Treatment of Metastatic Melanoma: Role of Monoclonal Antibodies in Targeted Immunotherapy. Introduction (Ref Art 610456 and 610457). (IDIS Note: CE Credit is for All Articles in the Issue, 610455-610457) *Am J Health-Syst Pharm* 2008, 65:S1-S2. (0.15 CEU)

Article Number 610454: Robinson RF. Hospital Pharmacists' Role in the Prevention and Management of Respiratory Syncytial Virus. (IDIS Note: The 1.5 Hour of CE Credit is for All Articles in the Issue, Article Numbers 610452-610454). *Am J Health-Syst Pharm* 2008, 65:S20-S22. (0.15 CEU)

Article Number 610453: Forbes M. Strategies for Preventing Respiratory Syncytial Virus. (IDIS Note: The 1.5 Hours of CE Credit is for All Articles in the Issue, Article Numbers 610452-610454). *Am J Health-Syst Pharm* 2008, 65:S13-S19. (0.15 CEU)

Article Number: 610452: Checchia P. Identification and Management of Severe Respiratory Syncytial Virus. (IDIS Note: The 1.5 Hours of CE Credit is for All Articles in the Issue, Article Numbers 610452-610454). *Am J Health-Syst Pharm* 2008, 65:S7-S12. (0.15 CEU)

Article Number 610126: Anonymous. Drugs for Hypertension. *Treat Guidel Med Lett* 2009, 7:1-10. (0.2 CEU)

Article Number 609746: Cziraky MJ, Watson KE, Talbert RL. Targeting Low HDL-Cholesterol to Decrease Residual Cardiovascular Risk in the Managed Care Setting. *J Manag Care Pharm* 2008, 14:S1-S31. (0.1 CEU)

Article Number 609647: Anonymous. Alvimopan (Entereg) for Postoperative Ileus. (IDIS Note: The 1.0 Hour of CE Credit is for All Articles in the Issue. Please Note Only This Article is Indexed, However All Pages of the Issue are Included Here, 93-96 and CE). *Med Lett Drugs Ther* 2008, 50:93-94. (0.1 CEU)

Article Number 609646: Anonymous. Bendamustine (Treanda) for CLL and NHL. (IDIS Note: The 1.0 Hour of CE Credit is for All Articles in the Issue, Article Numbers 609644-609646). (Erratum) (Art 609648). *Med Lett Drugs Ther* 2008, 50:91-92. (0.1 CEU)

Article Number 609645: Anonymous. Safety of SSRIS in Pregnancy. (IDIS Note: The 1.0 Hour of CE Credit is For All Articles in the Issue, Article Numbers 609644-609646). *Med Lett Drugs Ther* 2008, 50:89-91.

Article Number 609644: Anonymous. Advertisements for TNF Inhibitors. (IDIS Note: The 1.0 Hour of CE Credit is for All Articles in the Issue, Article Numbers 609644-609646). *Med Lett Drugs Ther* 2008, 50:89. (0.1 CEU)

Article Number 609469: Crouch MA, Fanikos J, Rihn TL. Advances in Anticoagulant Therapy to Support Primary Percutaneous Coronary Intervention. *Formulary* 2008, 43:2-15. (0.15 CEU)

Article Number 609286: Cada DJ, Levien TL, Baker DE. Regadenoson Injection. *Hosp Pharm* 2009, 44:57-68. (0.15 CEU)

Article Number 609222: Vo T, Marcus KB. Ranirestat: A Selective Aldose Reductase Inhibitor for Diabetic Sensorimotor Polyneuropathy. *J Pharm Technology* 2008, 24:340-344. (0.5 CEU)

Article Number 608894: Cada DJ, Levien TL, Baker DE. Certolizumab Pegol. *Hosp Pharm* 2008, 43:998-1010. (0.15 CEU)

FDA APPROVAL PACKAGES

Article Numbers: 609410-609421. Romiplostim, Nplate. FDA Approval Package 2008.

Article Numbers: 609398--609409. Tetrabenazine, Xenazine. FDA Approval Package 2008.

FDA ADVISORY COMMITTEE MEETINGS

Article Numbers 609625-609630: Arthritis Drug Advisory Committee, November 24, 2008. FDA Advisory Committee 2008.

Article Numbers 609618-609624: Joint Meeting of the Antiviral Drugs Advisory Committee and the Nonprescription Drugs Advisory Committee, October 29, 2008. FDA Advisory Committee 2008.

NEW DESCRIPTOR

PRIORITY CLINICAL PRACTICE GUIDELINE 168

Abbreviation: PRIORITY CLIN PRACT GUIDE

Major category: ARTICLE CLASSIFICATION

Subcategory: DESIGN/ANALYSIS

Evidence-based clinical practice guidelines are systematically developed statements to assist practitioner and patient decisions about health care for specific circumstances. These guidelines are developed by professional societies and associations, national health authorities, and other groups.

To assign descriptor 168, the Iowa Drug Information Service makes an editorial decision to select guidelines that it considers to be of high priority based on several factors including: methodology used for guideline preparation; characteristics of the health condition; potential benefits of guideline implementation; guideline recommendations are presented clearly and graded based on the evidence; and editorial independence of the developer.

For further details of selection criteria see: Moores KG. Evidence-based clinical practice guidelines. In: Malone PM, ed. *Drug Information: A Guide for Pharmacists*. 3rd Ed New York: McGraw Hill, 2006 (Added February, 2009)